Courses | Page 2 | AUA University

Topic

Core Curriculum Related Education

Title	Category	Credit	Event Date	Price
The Changing Face of Advanced Prostate Cancer 2023 Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	This is an ongoing course on advanced prostate cancer at the annual AUA since 2012, and the changes over the last decade have been nothing less than breathtaking! In the early years, it was all about metastatic castrate-resistant prostate cancer (CRPC) with multiple new therapeutic advances starting in 2010 followed by novel oral hormonal therapies and a focus on bone-targeted agents. Later, the course expanded to cover hormone-sensitive (HS) advanced disease due to the new data on chemotherapy and novel ADT extending survival in new M1 patients.
PARPi: Genetic Testing in Advanced Prostate Cancer - When and Who to Test Webcast (2023)		1.00 AMA PRA Category 1 Credit™ 1.00 Non-Physician Participation		$0.00	The American Urological Association (AUA) has developed a series of live virtual and on-demand educational offerings to further address the identified educational gaps and barriers in advanced prostate cancer care. Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessments, a three-part educational series to update urologists and advanced practice providers (APPs) on PARP-inhibitor (PARPi) treatment in advanced prostate cancer is being offered.
PARPi: Management of Adverse Events Webcast (2024)		1.00 AMA PRA Category 1 Credit™ 1.00 Non-Physician Participation		$0.00	The American Urological Association (AUA) has developed a series of live virtual and on-demand educational offerings to further address the identified educational gaps and barriers in advanced prostate cancer care. Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessments, a three-part educational series to update urologists and advanced practice providers (APPs) on PARP-inhibitor (PARPi) treatment in advanced prostate cancer is being offered.
Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	This case-based interactive course describes the role of germline genetics in urological cancers and how the identification of an alteration may impact precision oncology. We will provide a concise and comprehensive review of hereditary cancer genetics, discuss genetic risk assessment, diagnosis and treatment for a range of hereditary kidney, adrenal, upper tract and prostate cancer syndromes. We will review current National Comprehensive Cancer Network and AUA Guidelines for genetic evaluation of patients with kidney, adrenal, upper tract and prostate cancers.
The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Webcast (2024)		4.75 AMA PRA Category 1 Credit™ 4.75 Non-Physician Participation		$0.00	This comprehensive, interactive course equips urologic professionals with the knowledge and skills needed to effectively manage patients with advanced prostate cancer. Through an in-depth exploration of guidelines, treatment modalities, and emerging therapies, participants will gain a thorough understanding of this complex disease and its evolving landscape.
Building a Primary Palliative Care Model for Urology Webcast (2021)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	Building a Primary Palliative Care Model for Urology Webcast (2021) discusses aspects of palliative care that benefit patients, the urologist’s role and their collaboration with palliative care clinicians including:
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	This is a repeat course from prior years, with review of advanced and metastatic prostate, bladder and kidney cancer. Most recent treatment guidelines are reviewed along with the studies that support them. Different disease spaces in oncologic care are discussed, including the medications used to treat them, their mechanism, side effects and efficacy. Role of the advanced practice provider is discussed for each tumor type. Finally, cases are presented along with management options for audience participation.
Upper Tract Urothelial Cancer (UTUC) Guidelines – An Interactive and Evidence-Based Course Highlighting the Full Spectrum of Disease via Case...		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	This course will draw from the newly developed AUA Guidelines for Upper Tract Urothelial Cancer to provide an interactive, case-based approach for management of complex cases with attendee involvement to enhance their knowledge of this challenging disease and provide a basis for practice improvement. Aspects such as optimizing initial workup and risk stratification, endoscopic techniques for biopsy and treatment, multidisciplinary management (e.g., coordinating with medical oncology, nephrology, genetic counseling) and surgical approaches will be stressed.
AUA Advanced Prostate Cancer Guidelines Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	This course will be comprehensive AUA Guidelines on advanced prostate cancer in the management and outcomes of men with advanced, metastatic and castrate-resistant prostate cancer (CRPC). The course will include risk stratification, germline testing, PET imaging, the use of androgen deprivation therapy in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer. Early treatment intensification and evidenced-based guidelines will be covered.
Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your Practice Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	There are multiple genomic tests and advanced imaging modalities (MRI, prostate-specific membrane antigen PET, etc.) currently available for men to detect and risk-stratify prostate cancer. The outcomes of these tests may lead to different detection strategies (observation, immediate biopsy, etc.) and treatment decisions (active surveillance, surgery, radiation, adjuvant therapy, etc.). We will also discuss germline testing as inherited mutations have considerable implications for screening, treatment, genetic counseling and cascade testing of family members.
Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	This is a tumor board-style course, with case presentations ranging from low-risk disease with conservative management to high-risk and metastatic disease requiring multidisciplinary management, that will highlight key issues in the care of patients with upper tract urothelial carcinoma (UTUC) and incorporate the AUA UTUC Guidelines. A multidisciplinary faculty panel will discuss their recommendations and their rationale. Key aspects that will be covered include: • Adequate staging, endoscopic evaluation and risk stratification with clinically validated tools.
Contemporary Pharmacotherapy for OAB 2024: Monotherapy and Combined Pharmacotherapy to Optimize Treatment Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation, and innovation.
Global Advancements in Bladder Cancer Webcast (2023)		1.50 AMA PRA Category 1 Credit™ 1.50 Non-Physician Participation		$0.00
Practical Implementation of Third-Line Therapies for Refractory Overactive Bladder (OAB) Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	Learners will be presented with case-based and guidelines-based information regarding when to introduce third-line therapies to patients for potentially refractory overactive bladder (OAB), presentation (scripting) techniques to impart important information to patients with user-friendly comprehensible language and analogies to help the patients receive the counseling, pros and cons of each of the third-line therapies, technical tips on optimal delivery of the three third-line therapies and how to select which therapies are the best fit for a given patient.
Treatment for Hormone Sensitive Prostate Cancer Webcast (2023)		1.00 AMA PRA Category 1 Credit™ 1.00 Non-Physician Participation		$0.00

Pages